Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors

Abstract

The present invention provides a method for treating fibromyalgia and/or chronic fatigue syndrome by administering an antagonist or partial agonist of 5HT1a receptors.

What is claimed is:  
     
         1 . A method for treating fibromyalgia comprising administrating of an effective amount of an antagonist or partial agonist of 5HT1a receptors.  
     
     
         2 . A method for treating chronic fatigue syndrome comprising administrating of an effective amount of an antagonist or partial agonist of 5HT1a receptors.  
     
     
         3 . A method according to  claim 1  employing an effective amount of the racemic substance RS pindolol or a salt thereof.  
     
     
         4 . A method according to  claim 1  employing an effective amount of one of the enantiomers, S (−) pindolol or a salt thereof.  
     
     
         5 . A method according to  claim 1  in which effective amounts of RS-pindolol or S(−) pindolol or their salts are administered in a pharmaceutical dosage form that permits rapid release of the active substances.  
     
     
         6 . A method for treating fibromyalgia comprising administrating of an effective amount of an antagonist or partial agonist of 5HT1a receptors in which effective amounts of RS pindolol or S(−) pindolol or their salts are administered in a pharmaceutical dosage form that releases the active substances in a controlled release form that permits administration of the active substances at lesser frequency than in  claim 5 .  
     
     
         7 . A method according to  claim 1  in which the diseases are characterised as fibromyalgia and/or chronic fatigue syndrome.  
     
     
         8 . A method according to  claim 2  employing an effective amount of the racemic substance RS pindolol or a salt thereof.  
     
     
         9 . A method according to  claim 2  employing an effective amount of one of the enantiomers, S (−) pindolol or a salt thereof.  
     
     
         10 . A method according to  claim 2  in which effective amounts of RS-pindolol or S(−) pindolol or their salts are administered in a pharmaceutical dosage form that permits rapid release of the active substances.  
     
     
         11 . A method for treating chronic fatigue syndrome comprising administrating of an effective amount of an antagonist or partial agonist of 5HT1a receptors in which effective amounts of RS pindolol or S(−) pindolol or their salts are administered in a pharmaceutical dosage form that releases the active substances in a controlled release form that permits administration of the active substances at lesser frequency than in  claim 5 .  
     
     
         12 . A method according to  claim 2  in which the diseases are characterised as fibromyalgia and/or chronic fatigue syndrome.